Avacincaptad Pegol

Summary

Avacincaptad Pegol (CHEMBL6068573) is a phase-3 clinical-stage oligonucleotide (ATC S01XA32); indicated across 3 conditions including age-related macular degeneration and eye disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• ATC class: S01XA32
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068573
Name	Avacincaptad Pegol
Type	Oligonucleotide
Max phase	3
ATC	S01XA32

Also known as: ARC-1905 FREE ACID, Avacincaptad pegol, Zimura, AVACINCAPTAD PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
eye disorder	-1	MONDO:0005328	EFO:0003966

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	2
PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06970665	PHASE4	RECRUITING	A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
NCT02686658	PHASE2/PHASE3	COMPLETED	Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NCT04435366	PHASE3	COMPLETED	A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
NCT05536297	PHASE3	COMPLETED	Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NCT02397954	PHASE2	COMPLETED	A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
NCT03362190	PHASE2	COMPLETED	ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
NCT03364153	PHASE2	COMPLETED	Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
NCT03374670	PHASE2	WITHDRAWN	ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
NCT05571267	PHASE2	TERMINATED	Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
NCT00709527	PHASE1	COMPLETED	ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
NCT00950638	PHASE1	COMPLETED	A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).